

# Chapter 57

## Cicatricial Pemphigoid

Kim B. Yancey

### REFERENCES

1. Oyama N et al: Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: The pathogenic relevance to HLA class II alleles and disease severity. *Br J Dermatol* **154**:90, 2006
2. Chan LS et al.: The first international consensus on mucous membrane pemphigoid: Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. *Arch Dermatol* **138**:370, 2002
3. Fleming TE, Korman NJ: Cicatricial pemphigoid. *J Am Acad Dermatol* **43**:571, 2000
4. Yancey KB, Egan CA: Pemphigoid: Clinical, histologic, immunopathologic, and therapeutic considerations. *JAMA* **284**:350-356, 2000
5. Bean SF et al: Cicatricial pemphigoid: Immunofluorescent studies. *Arch Dermatol* **106**:195, 1972
6. Lever WF: *Pemphigus and Pemphigoid*. Springfield, IL, Charles C. Thomas, 1965
7. Bernard P et al: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. *Arch Dermatol* **131**:48, 1995
8. Zillikens D et al: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. *Arch Dermatol* **131**:957, 1995
9. Laskaris G et al: Bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris. A comparative clinical survey of 278 cases. *Oral Surg Oral Med Oral Pathol* **54**:656, 1982
10. Setterfield J et al: Mucous membrane pemphigoid: HLA-DQB1\*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. *Br J Dermatol* **145**:406, 2001
11. Chan LS et al: Significantly increased occurrence of HLA-DQB1\*0301 allele in patients with ocular cicatricial pemphigoid. *J Invest Dermatol* **108**:129-132, 1997
12. Delgado JC et al: A common major histocompatibility complex class II allele HLA-DQB1\* 0301 is present in clinical variants of pemphigoid. *Proc Natl Acad Sci U S A* **93**:8569, 1996
13. Yunis JJ et al: Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. *Proc Natl Acad Sci U S A* **91**:7747, 1994
14. Ahmed AR et al: Association of DQw7 (DQB1\*0301) with ocular cicatricial pemphigoid. *Proc Natl Acad Sci U S A* **88**:11579, 1991.
15. Olasz EB, Yancey KB: Bullous pemphigoid and related subepidermal autoimmune blistering diseases. *Curr Dir Autoimmun* **10**:141, 2008
16. Rashid KA et al: Identification of an epitope within human integrin alpha 6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid. *J Immunol* **176**:1968, 2006
17. Chan RY et al: The role of antibody to human beta 4 integrin in conjunctival basement membrane separation: Possible in vitro model for ocular cicatricial pemphigoid. *Invest Ophthalmol Vis Sci* **40**:2283, 1999
18. Luke MC et al: Mucosal morbidity in patients with epidermolysis bullosa acquisita. *Arch Dermatol* **135**:954, 1999
19. Lazarova Z et al: Anti-epiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). *Br J Dermatol* **139**:791, 1998
20. Bedane C et al: Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: Evidence that BP180 spans the lamina lucida. *J Invest Dermatol* **108**:901, 1997
21. Chan LS et al: Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. *J Invest Dermatol* **108**:848, 1997
22. Balding SD et al: Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. *J Invest Dermatol* **106**:141, 1996
23. Ghohestani RF et al: Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. *J Invest Dermatol* **107**:136, 1996

24. Tyagi S et al: Ocular cicatricial pemphigoid antigen: Partial sequence and biochemical characterization. *Proc Natl Acad Sci U S A* **93**:14714, 1996
25. Kirtschig G et al: Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. *J Invest Dermatol* **105**:543-548, 1995
26. Shimizu H et al: Autoantibodies from patients with cicatricial pemphigoid target different sites in epidermal basement membrane. *J Invest Dermatol* **104**:370, 1995
27. Domloge-Hultsch N et al: Anti-epiligrin cicatricial pemphigoid. A subepithelial bullous disorder. *Arch Dermatol* **130**:1521, 1994
28. Mohimen A et al: Detection and partial characterization of ocular cicatricial pemphigoid antigens on COLO and SCaBER tumor cell lines. *Curr Eye Res* **12**:741, 1993
29. Bernard P et al: The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. *J Invest Dermatol* **99**:174, 1992
30. Domloge-Hultsch N et al: Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. *J Clin Invest* **90**:1628, 1992
31. Lazarova Z et al: IgG anti-laminin 332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid. *J Am Acad Dermatol* **58**:951, 2008
32. Liu Z et al: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. *J Clin Invest* **92**:2480, 1993
33. Nishie W et al: Humanization of autoantigen. *Nature Med* **13**:378, 2007
34. Lazarova Z et al: Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. *J Clin Invest* **98**:1509, 1996
35. Lazarova Z et al: Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model. *J Invest Dermatol* **114**:178, 2000
36. Woodley DT et al: Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. *J Invest Dermatol* **126**:1323, 2006
37. Sitaru C et al: Induction of dermal-epidermal separation in mice by passive transfer of antibodies to type VII collagen. *J Clin Invest* **115**:870, 2005
38. Woodley DT et al: Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. *J Invest Dermatol* **124**:958, 2005
39. Saw VP et al: Conjunctival interleukin-13 expression in mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro. *Am J Pathol* **175**:2406, 2009
40. Setterfield J et al: Cicatricial pemphigoid: Serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity. *Br J Dermatol* **140**:645, 1999
41. Egan CA et al: The immunoglobulin A antibody response in clinical subsets of mucous membrane pemphigoid. *Dermatology* **198**:330, 1999
42. Setterfield J et al: Mucous membrane pemphigoid: A dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. *Br J Dermatol* **138**:602, 1998
43. Rogers RS III et al: Desquamative gingivitis: Clinical, histopathologic, immunopathologic, and therapeutic observations. *J Am Acad Dermatol* **7**:729, 1982
44. Thorne JE et al: Mucous membrane pemphigoid and pseudopemphigoid. *Ophthalmology* **111**:45, 2004
45. Foster CS: Cicatricial pemphigoid. *Trans Am Ophthalmol* **84**:527, 1986
46. Lazor JB et al: Management of airway obstruction in cicatricial pemphigoid. *Laryngoscope* **106**:1014, 1996
47. Egan CA et al: Anti-epiligrin cicatricial pemphigoid: Clinical findings, immunopathogenesis, and significant associations. *Medicine (Baltimore)* **82**:177, 2003
48. Egan CA et al: Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. *Lancet* **357**:1850, 2001
49. Matsushima S et al: A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: Review of Japanese cases and evaluation of risk for internal malignancy. *J Dermatol* **31**:10, 2004
50. Chamberlain AJ et al: Paraneoplastic immunobullous disease with an epidermolysis bullosa acquisita phenotype: Two cases demonstrating remission with treatment of gynaecological malignancy. *Australas J Dermatol* **45**:136, 2004
51. Shannon JF et al: Cicatricial pemphigoid in non-Hodgkin's lymphoma. *Intern Med J* **33**:396, 2003

52. Parisi E et al: Modification to the approach of the diagnosis of mucous membrane pemphigoid: A case report and literature review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **95**:182, 2003
53. Sadler E et al: A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. *J Dermatol Sci* **47**:1, 2007
54. Fukushima S et al: Two cases of anti-epiligrin cicatricial pemphigoid with and without associated malignancy. *Acta Derm Venereol* **88**:484, 2008
55. Mitsuya J et al: Metastatic ovarian carcinoma-associated subepidermal blistering disease with autoantibodies to both the p200 dermal antigen and the gamma 2 subunit of laminin 5 showing unusual clinical features. *Br J Dermatol* **158**:1354, 2008
56. Demitsu T et al: A case of mucous membrane pemphigoid with IgG antibodies against all the alpha3, beta3, and gamma2 subunits of laminin 332 and BP180 C-terminal domain, associated with pancreatic cancer. *Clin Exp Dermatol* **34**:992, 2009
57. Takahara M et al: Mucous membrane pemphigoid with antibodies to the beta (3) subunit of laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease. *Dermatology* **219**:361, 2009
58. Malik M et al: Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. *J Oral Pathol Med* **36**:1, 2007
59. Letko E et al: Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the beta4 integrin subunit. *Clin Exp Dermatol* **32**:637, 2007
60. Brunsting LA, Perry HO: Benign pemphigoid? A report of seven cases with chronic, scarring, herpetiform plaques about the head and neck. *Arch Dermatol* **75**:489, 1957
61. Joly P et al: Brunsting-Perry cicatricial bullous pemphigoid: A clinical variant of localized acquired epidermolysis bullosa? *J Am Acad Dermatol* **28**:89, 1993
62. Mutasim DF et al: Cicatricial pemphigoid. *Dermatol Clin* **11**:499, 1993
63. Rose C et al: Histopathology of anti-laminin 5 mucous membrane pemphigoid. *J Am Acad Dermatol* **61**:433, 2009
64. Bernard P et al: Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis. *J Invest Dermatol* **94**:630, 1990
65. Meyer JR et al: Localization of basement membrane components in mucous membrane pemphigoid. *J Invest Dermatol* **84**:105, 1985
66. Fine JD et al: Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. *J Invest Dermatol* **82**:39, 1984
67. Hsu R et al: Noncomplement fixing, IgG4 autoantibodies predominate in patients with anti-epiligrin cicatricial pemphigoid. *J Invest Dermatol* **109**:557, 1997
68. Leonard JN et al: The relationship between linear IgA disease and benign mucous membrane pemphigoid. *Br J Dermatol* **110**:307, 1984
69. Domloge-Hultsch N, et al: Direct immunofluorescence microscopy of 1 mol/L sodium chloride-treated patient skin. *J Am Acad Dermatol* **24**:946, 1991
70. Gammon WR et al: Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. *J Am Acad Dermatol* **22**:664, 1990
71. Sarret Y et al: Salt-split human skin substrate for the immunofluorescent screening of serum from patients with cicatricial pemphigoid and a new method of immunoprecipitation with IgA antibodies. *J Am Acad Dermatol* **24**:952, 1991
72. Lazarova Z, Yancey KB: Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin. Specificity, sensitivity, and practical considerations. *J Am Acad Dermatol* **35**:398, 1996
73. Kelly SE, Wojnarowska F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. *Br J Dermatol* **118**:31, 1988
74. Marren P et al: Vulval cicatricial pemphigoid may mimic lichen sclerosus. *Br J Dermatol* **134**:522, 1996
75. Chan LS et al: Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. *JAMA* **266**:1543, 1991
76. Kirtschig G et al: Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: A systematic literature review. *Arch Dermatol* **138**:380, 2002
77. Lazarova Z, Yancey KB: Cicatricial pemphigoid: Immunopathogenesis and treatment. *Dermatol Ther* **15**:382, 2002
78. Anhalt GJ, Morrison LH: Bullous and cicatricial pemphigoid. *J Autoimmun* **4**:17, 1991

79. Assmann T et al: Topical tacrolimus for oral cicatricial pemphigoid. *Clin Exp Dermatol* **29**:674, 2004
80. Hall VC et al: Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. *Arch Dermatol* **139**:1083, 2003
81. Aufdemorte TB et al: Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid. *Oral Surg Oral Med Oral Pathol* **59**:256, 1985
82. Rogers RS III et al: Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. *J Am Acad Dermatol* **6**:215, 1982
83. Megahed M et al: Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. *J Am Acad Dermatol* **45**:256, 2001
84. Korman NJ: Update on the use of cyclophosphamide in the management of pemphigus, bullous pemphigoid, and cicatricial pemphigoid. *Med Surg Dermatol* **5**:1, 1998
85. Pandya AG et al: Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide. *Arch Dermatol* **133**:245, 1997
86. Korman NJ: Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid. *Med Surg Dermatol* **3**:209, 1996
87. Wetter DA et al: Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo Clinic experience. *Mayo Clin Proc* **80**:41, 2005
88. Ahmed AR, Dahl MV: Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. *Arch Dermatol* **139**:1051, 2003
89. Foster CS, Ahmed AR: Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study. *Ophthalmology* **106**:2136, 1999
90. Urcelay ML et al: Cicatricial pemphigoid treated with intravenous immunoglobulin. *Br J Dermatol* **137**:477, 1997
91. Dupuy A et al: Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). *Arch Dermatol* **140**:91, 2004
92. Sacher C et al: Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. *J Am Acad Dermatol* **46**:113, 2002